9.01
+0.44(+5.13%)
Currency In USD
| Previous Close | 8.57 |
| Open | 8.49 |
| Day High | 9.33 |
| Day Low | 8.05 |
| 52-Week High | 48.3 |
| 52-Week Low | 5.01 |
| Volume | 44,482 |
| Average Volume | 311,456 |
| Market Cap | 5.3M |
| PE | 0.01 |
| EPS | 958.65 |
| Moving Average 50 Days | 9.84 |
| Moving Average 200 Days | 8.96 |
| Change | 0.44 |
If you invested $1000 in Quoin Pharmaceuticals, Ltd. (QNRX) since IPO date, it would be worth $0.57 as of November 10, 2025 at a share price of $9.01. Whereas If you bought $1000 worth of Quoin Pharmaceuticals, Ltd. (QNRX) shares 5 years ago, it would be worth $8.21 as of November 10, 2025 at a share price of $9.01.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025
GlobeNewswire Inc.
Oct 30, 2025 12:30 PM GMT
ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provi
Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study
GlobeNewswire Inc.
Oct 28, 2025 12:30 PM GMT
Recruitment of Three Additional Pediatric Patients in Austria and Ireland Achieves Investigator Study TargetCurrent Pediatric Patient in Ongoing Study Has Completely Healed Skin After 9 months of ‘Whole Body’ TreatmentInvestigator’s Global Assessment
Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
GlobeNewswire Inc.
Oct 21, 2025 12:30 PM GMT
Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously granted by the European Medicines Agency in May 2025 ASHBURN, Va., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceu